Abstracts tagged "methotrexate (MTX)"

Abstract Number: 1338 • 2019 ACR/ARP Annual Meeting
Joint-specific Responses to Tofacitinib and Methotrexate in Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Start
Mojca Frank-Bertoncelj¹, Oliver Distler ², Tim Killeen ³, Kenneth Kwok ⁴, Lisy Wang ⁵, Caroline Ospelt ¹ and Adrian Ciurea ¹, ¹University Hospital Zürich, Zürich, Switzerland, ²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ³Pfizer AG, Zürich, Switzerland, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Despite systemic inflammatory cues, RA affects synovial joints variably. Tofacitinib is an oral JAK inhibitor for the treatment of RA. Previous post hoc analyses…
Abstract Number: 2401 • 2019 ACR/ARP Annual Meeting
Enhanced Methotrexate Polyglutamation in Japanese as Compared to Caucasian Rheumatoid Arthritis Patients Starting Methotrexate
Thierry Dervieux¹, Joel Kremer ², Kelley Brady ¹, Chihiro Takahashi ³, Tsutomu Takeuchi ⁴ and Yuko Kaneko ⁵, ¹Exagen, Vista, CA, ²Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY, ³Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ⁴Keio University Hospital Division of Rheumatology, Tokyo, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku, Tokyo, Japan
Background/Purpose: Methotrexate (MTX) is an anti-folate prodrug activated to MTX polyglutamates (MTXPGs). Japanese Rheumatoid Arthritis (RA) patients are thought to have heightened sensitivity to MTX…
Abstract Number: 1436 • 2019 ACR/ARP Annual Meeting
Analysis of Adverse Events of Methotrexate (MTX), bDMARDs and Tofacitinib (TOFA) Reported to Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Naonori Tsuda¹, Shigeko Inokuma ², Kenichi Hiraga ³, Yoshinori Masui ³ and Toshikazu Kano ³, ¹Kohondai Hospital, National Center for Global health and Medicine, Ichikawa, Chiba, Japan, ²Chiba Central Medical Center, Ichikawa, Chiba, Japan, ³Kohnodai Hospital, National Center for Global health and Medicine, Ichikawa, Chiba, Japan
Background/Purpose: Among DMARDs (disease modifying anti-rheumatic drugs), methotrexate (MTX), bDMARDs (biologic DMARDs) and JAK (Janus kinase) inhibitors are the major. Many adverse events of these…
Abstract Number: 2404 • 2019 ACR/ARP Annual Meeting
Does Combined Therapy Affects Adherence in Rheumatoid Arthritis?
Iván de Jesús Hernández-Galarza ¹, Rita Pineda-Sic¹, Marielva Castro-Gonzalez ¹, Diana Elsa Flores-Alvarado ¹, Octavio Ilizaliturri-Guerra ¹, Rodolfo Uriarte-Botello ¹ and Dionicio Galarza-Delgado ¹, ¹Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico
Background/Purpose: Treatment adherence in Rheumatoid Arthritis (RA) patients vary from 30 to 80%. It is important to identify the associated factors to a low adherence,…
Abstract Number: 1441 • 2019 ACR/ARP Annual Meeting
Is Background Methotrexate Still Advantageous in Extending TNF Drug Survival in the Elderly: An Analysis of the British Society for Rheumatology Biologics Register – Rheumatoid Arthritis
Katie Bechman¹, Anuoluwapo Oke ², Mark Yates ³, Sam Norton ³, Elaine Denderson ⁴, Andrew Cope ⁵ and James Galloway ², ¹Kings College London, London, England, United Kingdom, ²Kings College London, London, United Kingdom, ³Kings College London, London, ⁴MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, ⁵Academic Rheumatology, King's College London, London, United Kingdom
Background/Purpose: Long-term observational data from national registries in rheumatoid arthritis allow the examination of TNF drug survival rates. Despite a good initial response to a…
Abstract Number: 2476 • 2019 ACR/ARP Annual Meeting
Side Effects of Methotrexate and TNFi: Differences in Tolerability Among Patients with PsA and RA
Alexis Ogdie¹, Ervant Maksabedian ², Bradley Stolshek ², Yomei Shaw ³ and Kaleb Michaud ⁴, ¹University of Pennsylvania, Philadelphia, PA, ²Amgen Inc., Thousand Oaks, CA, ³FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ⁴FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS
Background/Purpose: Methotrexate (MTX) is generally well tolerated in rheumatoid arthritis (RA) but little is known about the tolerability of MTX in psoriatic arthritis (PsA). One…
Abstract Number: 1533 • 2019 ACR/ARP Annual Meeting
The Performance Characteristics of Composite Measures Used in a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis
Laura Coates¹, Joseph Merola ², Philip Mease ³, Alexis Ogdie ⁴, Dafna Gladman ⁵, Vibeke Strand ⁶, Leonieke van Mens ⁷, Lyrica Liu ⁸, Priscilla K Yen ⁸, David Collier ⁸, Gregory Kricorian ⁸, James Chung ⁸ and Philip Helliwell ⁹, ¹University of Oxford, Oxford, United Kingdom, ²Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ³Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ⁴Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁶Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ⁷University of Amsterdam, Amsterdam, Netherlands, ⁸Amgen Inc., Thousand Oaks, CA, ⁹University of Leeds, Leeds, United Kingdom
Background/Purpose: Composite measures of disease activity are used in psoriatic arthritis (PsA), but their relative performance and contributions of individual components to overall scores are…
Abstract Number: 2860 • 2019 ACR/ARP Annual Meeting
Perturbation of the Human Gut Microbiome by Methotrexate Contributes to the Resolution of Inflammation and Autoimmune Disease
Renuka Nayak¹, Margaret Alexander ¹, Kye Stapleton-Grey ², Carles Ubeda ³, Jose Scher ⁴ and Peter Turnbaugh ¹, ¹UCSF, San Francisco, ²Carnegie Mellon, Pittsburg, ³Centro Superior de Investigación en Salud Pública - FISABIO, Valencia, Spain, ⁴Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY
Background/Purpose: The trillions of microorganisms (microbiota) found within the human gut play a critical role in shaping the immune system, yet these complex microbial communities…
Abstract Number: 1759 • 2019 ACR/ARP Annual Meeting
Methotrexate in Patients with Hand Erosive Osteoarthritis Refractory to Usual Treatments: A Randomized, Double-blind, Placebo-controlled Trial
stéphanie Ferrero ¹, Ruth Wittoek ², Edem Allado ³, Coralie Cruzel ⁴, Véronique Breuil ¹, Liana Euller Ziegler ⁵, Damien louille ⁶, Christian Roux⁷ and Joel Kremer ⁸, ¹University of Nice, nice, France, ²Ghent University Hospital, Gent University, Gent, Belgium, ³Centre Hospitalier Universitaire de Nancy, Nancy, France, ⁴Université Cote d'Azur, nice, France, ⁵PUPH CHU NICE, nice, France, ⁶Université Cote d'Azur, Nancy, France, ⁷Université Cote d'Azur, Nice, ⁸Albany Medical College, Albany, NY
Background/Purpose: No studies have assessed the effect of methotrexate (MTX) in osteoarthritis of the hand (HOA). The purpose of our study was to examine the…
Abstract Number: 1890 • 2019 ACR/ARP Annual Meeting
Methotrexate Adverse Events in a Randomized Double-Blind Placebo-Controlled Trial:Results from the Cardiovascular Inflammation Reduction Trial (CIRT)
Daniel Solomon¹, Robert Glynn ², Elizabeth Karlson ³, Fengxin Lu ³, Cassandra Corrigan ³, Joshua Colls ³, Chang Xu ³, Jean MacFadyen ³, Medha Barbhaiya ⁴, Nancy Berliner ³, Paul Dellaripa ³, Brendan Everett ³, Sara Hammond ³, Meredith Murray ³, Deepak Rao ³, Susan Ritter ⁵, Anna Rutherford ⁵, Jeffrey Sparks ³, Jacklyn Stratton ⁵, Dong Suh ³, Sara K. Tedeschi ⁶, Kathleen Vanni ³, Nina Paynter ⁵ and Paul Ridker ⁵, ¹Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ²Harvard Medical School - Boston, MA, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵Brigham and Women's Hospital, Boston, ⁶Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA
Background/Purpose: Prior observational studies have estimated the risk of adverse events with low dose methotrexate (MTX). However, prior randomized controlled trials (RCT) were too small…
Abstract Number: 1909 • 2019 ACR/ARP Annual Meeting
miR-21-5p Expression as a Marker of Treatment Response in Psoriatic Arthritis Patients
Rohan Machhar¹, Justine (Yang) Ye ², Remy Pollock ¹ and Dafna Gladman ³, ¹Krembil Research Institute, University Health Network, Toronto, Canada, ²University Health Network, University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis occurring in patients with psoriasis. Links between altered miRNA expression with the pathogenesis of several autoimmune disorders…
Abstract Number: 2067 • 2019 ACR/ARP Annual Meeting
Comparison of Medication New User Definitions in Multi-Specialty EMR Data
Jeffrey Curtis¹, Lang Chen ¹, Narender Annapureddy ², Cassie Clinton ¹, Megan Clowse ³, Millie Long ⁴, W. Benjamin Nowell ⁵, Jim Oates ⁶, Rennie Rhee ⁷, Siddarth Singh ⁸, Fenglong Xie ⁹ and Timothy Beukelman ¹⁰, ¹University of Alabama at Birmingham, Birmingham, AL, ²Vanderbilt University, Nashville, TN, ³Duke University, Durham, ⁴University of North Carolina Chapel Hill, Chapel Hill, NC, ⁵Global Healthy Living Foundation, Upper Nyack, NY, ⁶Division of Rheumatology & Immunology/Medical University of South Carolina, Charleston, SC, ⁷University of Pennsylvania, Division of Rheumatology, Philadelphia, PA, ⁸University California, San Diego, San Diego, ⁹University of Alabama at Birmingham, Birmingham, ¹⁰University of Alabama Birmingham, Birmingham, AL
Background/Purpose: New user designs are typically preferred in pharmacoepidemiology to avoid bias. The optimal implementation of a new user design in electronic medical record (EMR)…
Abstract Number: 2256 • 2019 ACR/ARP Annual Meeting
Patient Beliefs and Perceptions of Methotrexate for the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis
W. Benjamin Nowell¹, Elaine Karis ², Kelly Gavigan ¹, Laura Stradford ¹, Scott Stryker ³, Shilpa Venkatachalam ¹, Gregory Kricorian ³ and Jeffrey Curtis ⁴, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Amgen Inc, Thousand Oaks, CA, ³Amgen Inc., Thousand Oaks, CA, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX) is a frequently used therapy in both Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) due to its beneficial effects in both populations.…
Abstract Number: L06 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Filgotinib in a Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic Dmards
Mark C. Genovese¹, Kenneth C. Kalunian², David Walker³, Jacques-Eric Gottenberg⁴, Kurt de Vlam⁵, Neelufar Mozaffarian⁶, Beatrix Bartok⁶, Franziska Matzkies⁶, Jie Gao⁶, Ying Guo⁶, Chantal Tasset⁷, John S. Sundy⁶ and Tsutomu Takeuchi⁸, ¹Division of Immunology & Rheumatology, Stanford University, Stanford, CA, ²Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ³Northumbria Healthcare, United Kingdom, United Kingdom, ⁴Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁵Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, ⁶Gilead Sciences, Inc., Foster City, CA, ⁷Galapagos NV, Mechelen, Belgium, Mechelen, Belgium, ⁸Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in phase 2 studies of active RA in patients (pts) with insufficient…
Abstract Number: L11 • 2018 ACR/ARHP Annual Meeting
Etanercept and Methotrexate As Monotherapy or in Combination in Patients with Psoriatic Arthritis: A Phase 3, Double-Blind, Randomized Controlled Study
Philip J. Mease¹, Dafna D. Gladman², David H. Collier³, Christopher T. Ritchlin⁴, Philip S. Helliwell⁵, Lyrica Liu⁶, Gregory J. Kricorian³ and James B. Chung³, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²University of Toronto, Toronto, ON, Canada, ³Amgen Inc., Thousand Oaks, CA, ⁴University of Rochester Medical Center, Rochester, NY, ⁵University of Leeds, Leeds, United Kingdom, ⁶Amgen Inc., South San Francisco, CA
Background/Purpose: Methotrexate (MTX) and tumor necrosis factor inhibitors (TNFi) such as etanercept (ETN) are often prescribed for psoriatic arthritis (PsA) either alone or in combination,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].